The hypothesis-generating findings suggest that spatial coordination topology is associated with the immunotherapy response in HCC and provide a principled graph-based framework for developing and evaluating future spatial biomarkers.
Abstract
The response to immune checkpoint blockade in hepatocellular carcinoma (HCC) remains highly variable, and the abundance of immune cells alone has been shown to be insufficient as a predictive biomarker. We analyse spatial transcriptomics data from seven neoadjuvant cabozantinib- and nivolumab-treated HCC patients to test whether the therapeutic outcome is associated with spatial coordination of multicellular programs rather than their presence. Modeling immune, stromal, and malignant transcriptional programs as continuous spatial fields, we introduce a graph-based framework that quantifies their organization using field energy and inter-program gradient coupling. Across tumors, immune exhaustion and cytotoxic programs display a comparable spatial structure irrespective of response, indicating that immune presence is not discriminatory. In contrast, responding tumors exhibit structured cancer-associated fibroblast organization and permissive malignant-stromal interfaces, whereas non-responders show pronounced malignant-CAF segregation and immune exclusion. Integrating three biologically motivated coupling terms, we define a Spatial Immune Coordination Index (SICI) that shows directionally consistent separation of response states across 21 of 27 coefficient parameterisations under sign-flip sensitivity testing, independent of immune abundance. Malignant–CAF coupling is the primary discriminating metric (Cohen’s
$$d=2.40$$
, Cliff’s
$$\delta =+1.00$$
,
$$p_{\textrm{exact}}=0.029$$
,
$$n=7$$
). In an exploratory bulk RNA-seq analysis in TCGA-LIHC (
$$n = 533$$
), coordination-informed composite scores show statistically significant but modest associations with overall survival. These hypothesis-generating findings suggest that spatial coordination topology is associated with the immunotherapy response in HCC and provide a principled graph-based framework for developing and evaluating future spatial biomarkers.
A nine-gene transcriptional signature derived from Niche 9 was associated with atezolizumab-plus-bevacizumab response, enhanced lymphoid immune features, lower Tumour Immune Dysfunction and Exclusion scores, and favourable clinical outcomes in independent cohorts.
Ming-Xiu Cai, Kai-Heng Hu, H. Wang et al.· Cancers· 0 citations
The mechanisms through which malignant, myeloid, lymphoid, endothelial, and stromal populations interact across spatial niches are discussed, and how these maps can inform biomarker discovery, patient stratification, and rational combination therapy are examined.
It is shown that spatial CD8+ T-cell exclusion is associated with lower objective response rates and shorter progression-free survival in ICB-treated NSCLC patients, and further evaluation of spatial immune contexture as a complementary biomarker in ICB-treated patients is supported.
J. Guégan, B. Bonhomme, F. Peyraud et al.· Signal Transduction and Targ...· 0 citations
Immune checkpoint inhibitor (ICI) therapy has transformed melanoma treatment, yet many patients either fail to respond or develop resistance after an initial response. The cellular and spatial determinants within the tumor microenvironment (TME) that underlie these divergent ICI therapy outcomes remain poorly defined....
Sajib Chakraborty, E. Corrales, I. Godbole et al.· Genome Medicine· 0 citations
This work proposes that metabolite-driven remodeling of the tumor microenvironment is a major cause of intratumoral TLS failure and outlines biomarker-guided strategies to restore TLS competence, including inhibition of tumor-derived tryptophan metabolism to promote TLS maturation and enhance anti-PD-1 efficacy.
Yi-Feng Wang, Yan Li, Shu-Juan Wei et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.